drugset / Trial / NCT00068042

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

NCT00068042

Phase 4 Completed 100 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Timeline

Start
2003-04
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide
Subject Pegvisomant Protein / enzyme biologic

Indications